Prevalence of Kidney Cancer in Attendees for Combined Lung and Kidney Cancer Screening by Computed Tomography Scanning.
No Thumbnail Available
All Authors
Rossi, SH.
Kitt, J.
Godoy, A.
Farquhar, F.
Cartledge, J.
Kimuli, M.
Bailey, H.
Burbidge, S.
Hancock, N.
Marshall, C.
LTHT Author
Farquhar, Fiona
Cartledge, Jon
Kimuli, Michael
Bailey, Hannah
Burbidge, Simon
Rogerson, Suzanne
Callister, Matthew
Cartledge, Jon
Kimuli, Michael
Bailey, Hannah
Burbidge, Simon
Rogerson, Suzanne
Callister, Matthew
LTHT Department
Research & Innovation
Abdominal Medicine & Surgery
Urology
Radiology
Cardio-Respiratory
Respiratory Medicine
Abdominal Medicine & Surgery
Urology
Radiology
Cardio-Respiratory
Respiratory Medicine
Non Medic
Research Nurse
Research Nurse
Research Nurse
Publication Date
2025
Item Type
Journal Article
Language
Subject
Subject Headings
Abstract
Kidney cancer (KC) screening may be facilitated by targeting individuals at a higher risk and combining with other screening programmes. Previous estimates of the prevalence of screen-detected KC are outdated and do not enable an accurate assessment in a high-risk group. The Yorkshire Kidney Screening Trial (YKST) is a unique study of the feasibility of adding KC screening via an abdominal noncontrast computed tomography (CT) scan to the thoracic low-dose CT within a targeted lung cancer screening trial in ever smokers (Yorkshire Lung Screening Trial; YLST). Seventeen histologically confirmed KC cases were detected on thoracic CT in YLST (N = 6650; prevalence 0.26%; 95% confidence interval [CI] 0.15-0.41%), which has implications for future service planning to accommodate the investigation and treatment of screen-detected KC patients following the national adoption of lung cancer screening. Adding abdominal CT in YKST (n = 4019) identified an additional ten histologically confirmed KC patients (prevalence 0.25%; 95% CI 0.12-0.46%). In summary, using data from YKST, we report the first contemporary estimates of the prevalence of KC in high-risk individuals, key data required to plan future prospective screening studies.
Journal
European Urology Oncology